Ataxia telangiectasia mutated (ATM) is a serine/threonine kinase that plays a key role in the regulation of DNA damage pathways and checkpoint arrest. In recent years, there has been growing interest in ATM as a therapeutic target due to its association with cancer cell survival following genotoxic stress such as radio- and chemotherapy. Large-scale targeted drug screening campaigns have been hampered, however, by technical issues associated with the production of sufficient quantities of purified ATM and the availability of a suitable high-throughput assay. Using a purified, functionally active recombinant ATM and one of its physiological substrates, p53, we have developed an in vitro FRET-based activity assay that is suitable for high-throughput drug screening.
CITATION STYLE
Adams, P., Clark, J., Hawdon, S., Hill, J., & Plater, A. (2017). An HTRF® assay for the protein kinase ATM. In Methods in Molecular Biology (Vol. 1599, pp. 43–56). Humana Press Inc. https://doi.org/10.1007/978-1-4939-6955-5_4
Mendeley helps you to discover research relevant for your work.